The US government has launched a different kind of study that will assign drugs to patients based on their genes rather than the type of cancer they have.
The National Cancer Institute's NCI-MATCH trial will be a massive precision medicine experiment at more than 2,400 sites around the country.
Low Doses of Anti-Cancer Drugs May Protect Against Type- 1 Diabetes
Ground breaking research finding on anti-cancer drugs that could protect against type 1 diabetes comes as a welcome news to millions of diabetics worldwide.
Advertisement
About 3,000 patients will have their tumor genes sequenced to see what mutations or pathways fuel their disease. About 1,000 patients whose tumor characteristics most closely match one of the 20 or so gene-targeting drugs offered in the study will be put into groups of about 30 patients to get that drug.
"The goal is really to try to get the information faster, so when we see responses we can expand rapidly" and offer the drug more widely, said Dr. Douglas Lowy, the Cancer Institute's acting director.
!['Hen Factories' To Synthesize Cancer Drugs]( "'Hen Factories' To Synthesize Cancer Drugs")
A groundbreaking venture has been initiated by a group of researchers, whereby therapeutic proteins, essential in cancer-treatment, are mass-produced in the egg white of a certain breed of hen.
Many cancers share the same gene mutations and so a drug that targets one of these for a specific cancer, such as breast, may work against other types, such as lung. "We're hoping that a substantial minority of the patients that are tested will actually have rare or uncommon cancers" so more can be learned about what genes fuel them, Lowy said.
Dr. Richard Pazdur, cancer drugs chief at the Food and Drug Administration, warned that although everyone hopes that targeting drugs to gene mutations will improve survival, "this may be far more complex than we realize."
The FDA has never approved a drug that was not aimed at a specific tumor type such as breast cancer, but if a drug shows promise for a particular pathway involved in many tumor types, it could be approved for that use, he said.
Source: Medindia
'Hen Factories' To Synthesize Cancer Drugs
A groundbreaking venture has been initiated by a group of researchers, whereby therapeutic proteins, essential in cancer-treatment, are mass-produced in the egg white of a certain breed of hen.
Advertisement
Many cancers share the same gene mutations and so a drug that targets one of these for a specific cancer, such as breast, may work against other types, such as lung. "We're hoping that a substantial minority of the patients that are tested will actually have rare or uncommon cancers" so more can be learned about what genes fuel them, Lowy said.
Dr. Richard Pazdur, cancer drugs chief at the Food and Drug Administration, warned that although everyone hopes that targeting drugs to gene mutations will improve survival, "this may be far more complex than we realize."
The FDA has never approved a drug that was not aimed at a specific tumor type such as breast cancer, but if a drug shows promise for a particular pathway involved in many tumor types, it could be approved for that use, he said.
Source: Medindia
First-in-Class Drugs in Pipeline for Non-Small Cell Lung Cancer
Newer drugs are in the pipeline for the treatment of Non-Small Cell Lung Cancer (NSCLC) which will provide targeted treatment and hopefully improve the prognosis of patients with lung cancer.
Advertisement
Anti-cancer Treatment Could Become CheaperThe Re Do project is striving to reduce the cost of anticancer treatment by using some drugs available for other conditions for the treatment of cancer. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
The presence of painless swelling in the lymph nodes could potentially indicate lymphatic cancer, say experts.
Women tested at high risk for breast cancer using non-clinical genetic tests overlooking family history may decide to undergo unnecessary breast surgery.
Atezolizumab-bevacizumab drug combination can yield positive outcomes in terms of extended survival and the elimination of liver cancer.
Reflux disease manifests as acid regurgitation and heartburn and is a known risk factor for esophageal cancer.
